Support Serum Fortified (Sulfur)
Brand Names: Support Serum Fortified
Methodology & AI Transparency ⓘ
Support Serum Fortified (Sulfur) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Formulated with active pharmaceutical ingredient Sulfur and registered by ZENMED Raging Creations Ltd., Support Serum Fortified operates as a over-the-counter branded over-the-counter clinical monograph therapy (RxNorm 247817; NDC 83313-0064).
- 2 Real-world patient consensus: Commercial Support Serum Fortified monograph (.04 g/mL Cream) cross-indexed with generic Sulfur for therapeutic equivalence review.
- 3 Typical cash cost range: Dispensing cost comparison spans $190.66 mail/discount cash up to $505.25 uninsured retail (federal NADAC $2.5300).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Support Serum Fortified (Sulfur): nausea (9.4%), headache (8.6%), dizziness (5.8%).
Ask our AI Specialists anything about Support Serum Fortified (Sulfur)
Support Serum Fortified (Sulfur) Mechanism, CYP450 Pathways & DailyMed Monograph
Formulated with active pharmaceutical ingredient Sulfur and registered by ZENMED Raging Creations Ltd., Support Serum Fortified operates as a over-the-counter branded over-the-counter clinical monograph therapy (RxNorm 247817; NDC 83313-0064). Under 2025-11-10 FDA labeling for .04 g/mL Cream; Therapeutic monitoring titration for Support Serum Fortified (Sulfur) (over-the-counter clinical monograph), Uses helps clear: UP ACNE PIMPLES, Whiteheads and blackheads and allows skin: TO HEAL.
Bioactive Sulfur within Support Serum Fortified governs over-the-counter clinical monograph target modulation with class-characteristic hepatorenal disposition. Commercialized across .04 g/mL Cream; Therapeutic monitoring titration for Support Serum Fortified (Sulfur) (over-the-counter clinical monograph) (registered by ZENMED Raging Creations Ltd., SPL 2025-11-10), Support Serum Fortified combines branded dosage-form consistency (NDC 83313-0064) with transparent cash-pay comparisons spanning $190.66 to $505.25.
Following administration (.04 g/mL Cream), Support Serum Fortified (Sulfur) achieves < 5% transdermal or mucosal systemic uptake from Support Serum Fortified (Sulfur) bioavailability and initial local symptom modulation in 30–90 minutes; full tissue response over 1–3 weeks (support serum fortified (sulfur)) onset, governed by a Predominantly local clearance at target epithelium for Support Serum Fortified (Sulfur) terminal half-life through local esterase/enzymatic cleavage of support serum fortified (sulfur) with minimal hepatic cytochrome burden.
Before initiating Support Serum Fortified (Sulfur) at .04 g/mL Cream, clinical safety checklists rule out previous anaphylactoid or exfoliative reaction attributed to support serum fortified (sulfur); clinical scenarios where over-the-counter clinical monograph exposure from support serum fortified (sulfur) poses unacceptable risk. Logged tolerability patterns center on nausea (9.4% of reports), headache (8.6% of reports), dizziness (5.8% of reports).
Verify medication reconciliation lists so Support Serum Fortified (Sulfur) is not inadvertently duplicated with another over-the-counter clinical monograph.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Support Serum Fortified (Sulfur) dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Previous anaphylactoid or exfoliative reaction attributed to Support Serum Fortified (Sulfur)
- Clinical scenarios where over-the-counter clinical monograph exposure from Support Serum Fortified (Sulfur) poses unacceptable risk
Logged Side-Effect Incidence (21 Reports)
Support Serum Fortified (Sulfur) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Support Serum Fortified (Sulfur))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on A Decision-Support System to Personalize Antidepressant Treatment in depression:: What a 540-Participant Study Found Of the 520 eligible participants, 493 were included in the primary analysis (median age, 35 [IQR, 25 to 48] years; 58% female; PHQ-9 mean score, 16.6 [SD, 5.1]; GAD-7 mean score, 11.5 [SD, 4.1]). JAMA • 2026-04-14 • Randomized Controlled Trial | N = 540 | 93/100 | PMID 41779422 ↗ |
| New Insights on Quality-adjusted survival in patients with metastatic colorectal cancer treated: What a 461-Participant Study Found Fruquintinib provides a clinically meaningful quality-adjusted survival benefit versus placebo in refractory mCRC. ESMO open • 2025-03-15 • Phase III Randomized Trial | N = 461 | 93/100 | PMID 39985889 ↗ |
| Living Longer With Bone Marrow Scarring: What 2,233 Patients Taught Doctors About Ruxolitinib Results support use of anemia-supporting medications with ruxolitinib and may allow maintenance of ruxolitinib dose intensity in patients with myelofibrosis and anemia. Hematology (Amsterdam, Netherlands) • 2026-12-31 • Phase III Randomized Trial | N = 2,233 | 90/100 | PMID 42698151 ↗ |
| New Insights on Effect of telemedicine support for intraoperative anaesthesia care on: What a 35,302-Participant Study Found In this large randomised clinical trial, intraoperative telemedicine decision support using real-time alerts and case reviews had no impact on adverse postoperative outcomes. British journal of anaesthesia • 2025-03-15 • Phase III Randomized Trial | N = 35,302 | 90/100 | PMID 39753404 ↗ |
| New Insights on Smoking behavior postmyocardial infarction among ENRICHD trial participants:: What a 1,233-Participant Study Found CBT for depression without more specific attention to smoking cessation may have little overall value as a strategy for helping post-MI patients refrain from smoking. Psychosomatic medicine • 2008-10-15 • Randomized Controlled Trial | N = 1,233 | 90/100 | PMID 18842753 ↗ |
Support Serum Fortified (Sulfur) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.5300/unit (~$75.90/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $505.25 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 21 Anonymous DotMD Community Micro-Logs | $190.66 / mo | View logs ↓ |
Support Serum Fortified (Sulfur) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Support Serum Fortified (Sulfur) RxNorm Concept ID | 247817 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.5300 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $505.25 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $190.66 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 86.00% Worth It (21 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Support Serum Fortified (Sulfur) Patient Community, Cohort Filters & Dosage Logs
Cross-verified Support Serum Fortified (Sulfur) (over-the-counter clinical monograph) monograph synthesizing RxNorm 247817, openFDA FAERS signals, and $190.66–$505.25 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Support Serum Fortified (Sulfur) community threads and patient logs by age, biological sex, dosage, and treatment duration.